Carcinoid Heart Disease
dc.contributor.advisor | Fülöp, Tibor | |
dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Kardiológiai Intézet::Kardiológiai Klinika | hu_HU |
dc.contributor.author | Ramana, Krishna Sai | |
dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
dc.contributor.opponent | Gazdag, Annamária | |
dc.contributor.opponent | Jenei, Csaba | |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Belgyógyászati Intézet | hu_HU |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Kardiológiai Intézet::Kardiológiai Klinika | hu_HU |
dc.date.accessioned | 2021-06-16T11:15:53Z | |
dc.date.available | 2021-06-16T11:15:53Z | |
dc.date.created | 2020-08-27 | |
dc.description.abstract | Carcinoid Heart Disease (CaHD) is a valvular heart disease manifesting clinically as right sided Heart failure. CaHD is a complication of Carcinoid Syndrome which is caused by a Neuroendocrine Tumour. Serotonin is thought to be at the heart of CaHD pathogenesis. Tumour biomarkers and echocardiography are the mainstay of diagnosis. Pharmacotherapy involves using Somatostatin analogues, but currently Valvular Heart surgery is the only option offering a potential cure. | hu_HU |
dc.description.course | általános orvos | hu_HU |
dc.description.courselang | angol | hu_HU |
dc.description.degree | egységes, osztatlan | hu_HU |
dc.format.extent | 42 | hu_HU |
dc.identifier.uri | http://hdl.handle.net/2437/311165 | |
dc.language.iso | en | hu_HU |
dc.subject | Carcinoid Heart Disease | hu_HU |
dc.subject | Cardiology | hu_HU |
dc.subject | Valvular Heart Disease | hu_HU |
dc.subject | Heart Failure | hu_HU |
dc.subject | Serotonin | hu_HU |
dc.subject | Cardiac Surgery | hu_HU |
dc.subject | Carcinoid Syndrome | hu_HU |
dc.subject | Neuroendocrine Tumour | hu_HU |
dc.subject.dspace | DEENK Témalista::Orvostudomány::Kardiológia | hu_HU |
dc.title | Carcinoid Heart Disease | hu_HU |